Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.
The widespread clinical adoption of protein biomarkers with diagnostic, prognostic and/or predictive value remains a formidable challenge for the biomedical community. From discovery to validation, the path to biomarkers of clinical relevance abounds with many protein candidates, yet so few concrete examples have been substantiated. In this review, we focus on the recent adoption of selected reaction monitoring (SRM) of plasma proteins in the path to clinical use for a broad range of diseases including cancer, cardiovascular disease, genetic disorders and various metabolic disorders. Recent progress reveals a promising outlook for clinical applications using SRM, which now provides the routine analysis of clinically relevant protein markers at low nanogram per millilitre in plasma.
Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia.
Christoph
C
Krisp
Sarah A
SA
Randall
Matthew J
MJ
McKay
Mark P
MP
Molloy
D015415:Biomarkers / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D004314:Down Syndrome / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000175:diagnosis / Q000473:pathology
D015415:Biomarkers; D001798:Blood Proteins